Literature DB >> 32303709

Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).

Jae-Cheol Jo1, Jin Seok Kim2, Je-Hwan Lee3, Jung-Hee Lee3, Sung-Nam Lim4, Sang Min Lee5, Sung-Soo Yoon6, In-Ho Kim7, Sung Hwa Bae8, Yoo Jin Lee1, Yunsuk Choi1, Won-Sik Lee9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32303709     DOI： 10.1038/s41409-020-0908-3

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma.

Authors:  Ji-Won Kim; Hyun Jung Lee; Hyeon Gyu Yi; Byung-Su Kim; Soo-Mee Bang; Jin Seok Kim; Inho Kim; Sung-Soo Yoon; Jong Seok Lee; Chul Soo Kim; Seonyang Park; Byoung Kook Kim
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

Review 2.  Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.

Authors:  Alessandro Isidori; Anna Christofides; Giuseppe Visani
Journal:  Leuk Lymphoma       Date:  2016-05-31

3.  BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.

Authors:  Jeong Eun Kim; Dae Ho Lee; Changhoon Yoo; Shin Kim; Sang-We Kim; Jung-Shin Lee; Chan Jeong Park; Jooryung Huh; Cheolwon Suh
Journal:  Leuk Res       Date:  2010-08-03       Impact factor: 3.156

4.  BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.

Authors:  Jae-Cheol Jo; Byung Wook Kang; Geundoo Jang; Sun Jin Sym; Sung Sook Lee; Ja Eun Koo; Jong Wook Kim; Shin Kim; Jooryung Huh; Cheolwon Suh
Journal:  Ann Hematol       Date:  2007-08-21       Impact factor: 3.673

5.  Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

Authors:  Christian Gisselbrecht; Norbert Schmitz; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Noel J Milpied; John Radford; Nicolas Ketterer; Ofer Shpilberg; Ulrich Dührsen; Hans Hagberg; David D Ma; Andreas Viardot; Ray Lowenthal; Josette Brière; Gilles Salles; Craig H Moskowitz; Bertram Glass
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

6.  Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.

Authors:  Ho-Jin Shin; Won-Sik Lee; Ho-Seop Lee; Hawk Kim; Gyeong-Won Lee; Moo-Kon Song; Jin Seok Kim; Ho-Young Yhim; Joo Seop Chung
Journal:  Leuk Lymphoma       Date:  2014-03-07

7.  Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience.

Authors:  J Rodriguez; M D Caballero; A Gutierrez; C Solano; R Arranz; J J Lahuerta; J Sierra; M Gandarillas; J A Perez-Simon; J Zuazu; A Lopez-Guillermo; A Sureda; E Carreras; J Garcia-Laraña; J Marin; J C Garcia; A Fernandez De Sevilla; J Rifon; R Varela; I Jarque; C Albo; A Leon; J SanMiguel; E Conde
Journal:  Ann Oncol       Date:  2004-10       Impact factor: 32.976

8.  Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

Authors:  Francesco d'Amore; Thomas Relander; Grete F Lauritzsen; Esa Jantunen; Hans Hagberg; Harald Anderson; Harald Holte; Anders Österborg; Mats Merup; Peter Brown; Outi Kuittinen; Martin Erlanson; Bjørn Østenstad; Unn-Merete Fagerli; Ole V Gadeberg; Christer Sundström; Jan Delabie; Elisabeth Ralfkiaer; Martine Vornanen; Helle E Toldbod
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

9.  BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

Authors:  W Mills; R Chopra; A McMillan; R Pearce; D C Linch; A H Goldstone
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

10.  Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma.

Authors:  Jae-Cheol Jo; Dok Hyun Yoon; Shin Kim; Jung Sun Park; Chan-Sik Park; Jooryung Huh; Sang-Wook Lee; Jin-Sook Ryu; Cheolwon Suh
Journal:  Korean J Hematol       Date:  2012-06-26
  10 in total
  1 in total

1.  Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.

Authors:  Jae-Cheol Jo; Jin-Seok Kim; Je-Hwan Lee; Jung-Hee Lee; Seong Nam Im; Sang-Min Lee; Sung-Soo Yoon; In-Ho Kim; Seong Hwa Bae; Yoo Jin Lee; Yunsuk Choi; Won-Sik Lee
Journal:  Ann Hematol       Date:  2020-11-17       Impact factor: 3.673
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.